The agreement is the culmination of the partnership between binx health and Recipharm spanning many years and facilitates the bringing to market of what is expected to be a transformational diagnostics platform, providing almost instantaneous results to both patients and clinicians for the diagnosis of chlamydia and gonorrhoea. Recipharm will supply cartridges from the Kings Lynn operation in the United Kingdom.

Commenting on the agreement, Jeff Luber, CEO binx health, said: "I am very pleased we are further consolidating our relationship with Recipharm and look forward to developing this further with additional capacity. The opportunities for the binx io platform are enormous and it is important to us that we have a reliable partner".

Keyvan Djamarani, CEO of Bespak by Recipharm said: "We are excited to be part of this project and to be supporting the binx io platform. Point of Care (POC) testing is an under-exploited segment which will only grow and Recipharm sees this opportunity as a strategically important entry into this interesting business segment and highly complementary to the Bespak by Recipharm offering".

Recipharm is a minority investor in binx health.

Recipharm contacts
Keyvan Djamarani, CEO, Bespak by Recipharm, keyvan.djamarani@recipharm.com,+44 155 369 3421

For media enquiries, please contact Kate Hindhaugh at ramarketing: kate@ramarketingpr.com,+44 (0)191 222 1242, ramarketingpr.com, Twitter: @ramarketingpr,Facebook: /ramarketingpr, Linkedin: /ramarketing

Binx media contacts
Cassie Arnold, cassie@KMAandCo.com

About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm's annual turnover is approximately SEK 11 billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.

For more information on Recipharm and our services, please visit www.recipharm.com 

About binx health
binx health is a first-of-kind population health technology company that brings high quality convenient testing to the places where people live, work, study and shop. We work with large corporate partners and institutions to keep populations healthy and businesses and schools open. Our solutions broaden access to care for millions. Our point-of-care io platform puts central-lab quality testing solutions in the hands of clinicians everywhere, including the rapidly expanding ecosystem of retail health. Our suite of medically guideline-driven, at-home testing solutions bring high quality testing and population health tools and digital integration capability to large corporate partners and those unable to visit a clinic location. Our FDA cleared io platform is the first ever point-of-care tool for the detection of chlamydia and gonorrhea that provides central lab performance results in about thirty minutes. Our platform is highly flexible, easy-to-use and rapid, offering molecular point-of-care answers at central-lab quality performance and for the first time enabling single-visit test and treatment. We are currently expanding the platform COVID-19 testing combining our proprietary electrochemical detection with CRISPR methods. We are building solutions designed for the future of healthcare that lies at the nexus of testing convenience, rigorous science, and strong consumer relationships.

About binx IO Platform
The platform is the fastest molecular platform in the world that has U.S. Food and Drug Administration (FDA) clearance for chlamydia and gonorrhea testing. It is based on a proprietary detection method that makes it suitable for broad application across infectious diseases. It has a demonstrated ability to rapidly detect complex infectious disease targets from bodily fluids with very high accuracy and consists of an easy-to-use, desktop-sized instrument and single-use cartridge with multiplex capacity of up to 24 targets. Once a patient sample is added to the cartridge and loaded into the io instrument, the process is fully automated, requires no interpretation of data, and is designed to produce a clearly indicated onscreen "detected" or "not detected" result.